@article {Ohrndorfe001497, author = {Sarah Ohrndorf and Anne-Marie Glimm and Mads Ammitzb{\o}ll-Danielsen and Mikkel Ostergaard and Gerd R Burmester}, title = {Fluorescence optical imaging: ready for prime time?}, volume = {7}, number = {2}, elocation-id = {e001497}, year = {2021}, doi = {10.1136/rmdopen-2020-001497}, publisher = {BMJ Specialist Journals}, abstract = {The novel technique of fluorescence optical imaging (FOI, Xiralite), which is approved in the European Union and the USA for clinical use, has been the object of studies since 2009. Indocyanine green-based FOI can demonstrate an impaired microcirculation caused by inflammation in both hands in one examination. Several studies have investigated FOI for detection of joint inflammation by comparing FOI to magnetic resonance imaging (MRI) and/or musculoskeletal ultrasound (MSUS). The results have shown a generally good agreement (\>80\%) between FOI and clinical examination, MRI and MSUS by power Doppler in inflammatory joint diseases. Moreover, characteristic enhancements in skin and nails are seen in PsA, which potentially can be useful in the diagnostic process of early undifferentiated arthritis. Furthermore, FOI has been investigated for the visualisation of a disturbed microcirculation in the hands and fingers of patients with systemic sclerosis (SSc), highlighting the potential of monitoring vascular changes in SSc and other vasculopathies. The available data indicate that it is time to consider FOI as a useful part of the imaging repertoire in rheumatology clinical practice, particularly where MSUS and MRI are not easily available.}, URL = {https://rmdopen.bmj.com/content/7/2/e001497}, eprint = {https://rmdopen.bmj.com/content/7/2/e001497.full.pdf}, journal = {RMD Open} }